Reviewer’s report

Title: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

Version: 2 Date: 7 December 2012

Reviewer: Evan Gomes

Reviewer’s report:

Manuscript: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

Overview: This study by Olsson et al. aimed to investigate the presence of MDM2 promoter SNP309 polymorphism, p53 gene mutation, and expression of p53 and p16 in urinary bladder carcinoma stage T1 tumors. They also observed whether these targets correlated with any changes in tumor recurrence and progression.

Major and Minor Compulsory Revisions:

1. No revisions to the manuscript are required.

2. The objectives of this study were well-defined and the methodology employed was appropriate.

3. All outcomes, negative and positive, were carefully examined and reported.

4. The number of patient samples used for the study was significant and adequate to produce a convincing result.

5. The manuscript is clear and well written and meets the relevant standards for reporting and data deposition.

6. This is a noteworthy study with potential significance and impact.

Conclusion: The work has significant implications for human urinary bladder cancer and important clinical relevance. Publication of this manuscript will contribute positively to the field.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
No competing interests to report.